These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17205651)

  • 1. Anti-HIV agents. Darunavir shows its strength.
    TreatmentUpdate; 2006; 18(4):2-3. PubMed ID: 17205651
    [No Abstract]   [Full Text] [Related]  

  • 2. Amping amprenavir with ritonavir.
    TreatmentUpdate; 2001; 12(12):10. PubMed ID: 11570075
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug interactions. Amprenavir with low-dose ritonavir.
    TreatmentUpdate; 2006; 18(3):9-10. PubMed ID: 17211921
    [No Abstract]   [Full Text] [Related]  

  • 4. 48-week study results show DRV's staying power.
    Bernard EJ
    IAPAC Mon; 2007 Jan; 13(1):10-1. PubMed ID: 17523243
    [No Abstract]   [Full Text] [Related]  

  • 5. Darunavir now approved for use in treatment-naive patients.
    Sax PE
    AIDS Clin Care; 2008 Dec; 20(12):102. PubMed ID: 19271337
    [No Abstract]   [Full Text] [Related]  

  • 6. Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain.
    Pasquau J; Gostkorzewicz J; Ledesma F; Anceau A; Hill A; Moecklinghoff C
    Appl Health Econ Health Policy; 2012 Mar; 10(2):139-41. PubMed ID: 22293019
    [No Abstract]   [Full Text] [Related]  

  • 7. Darunavir: promising initial results.
    MacArthur RD
    Lancet; 2007 Apr; 369(9568):1143-4. PubMed ID: 17416241
    [No Abstract]   [Full Text] [Related]  

  • 8. Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.
    Edmunds-Ogbuokiri T
    HIV Clin; 2007; 19(1):1-3. PubMed ID: 17405221
    [No Abstract]   [Full Text] [Related]  

  • 9. Darunavir/ritonavir monotherapy in clinical practice.
    Parienti JJ
    AIDS; 2011 Jan; 25(1):119. PubMed ID: 21119326
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-HIV agents. Darunavir shows its strength.
    TreatmentUpdate; 2007; 19(5):2-4. PubMed ID: 17955613
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naïve patients: a pilot study.
    Nishijima T; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
    AIDS; 2012 Mar; 26(5):649-51. PubMed ID: 22233654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA clears HIV drug for patients with resistant virus.
    AIDS Read; 2006 Aug; 16(8):392. PubMed ID: 16933372
    [No Abstract]   [Full Text] [Related]  

  • 13. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
    MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases.
    Rawizza HE; Sax PE
    AIDS Read; 2008 Sep; 18(9):466-72, 478-9. PubMed ID: 18828231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower dose of ritonavir approved for use with fosamprenavir.
    Sax PE
    AIDS Clin Care; 2007 Dec; 19(12):106. PubMed ID: 18399004
    [No Abstract]   [Full Text] [Related]  

  • 17. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy.
    Valantin MA; Kolta S; Flandre P; Algarte Genin M; Meynard JL; Ponscarme D; Slama L; Cuzin L; de Kerviler E; Inaoui R; Katlama C
    HIV Med; 2012 Sep; 13(8):505-15. PubMed ID: 22416798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials.
    Poveda E; Vispo E; Pattery T; de Mendoza C; Villacian J; Soriano V
    J Antimicrob Chemother; 2007 Dec; 60(6):1411-3. PubMed ID: 17911388
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
    Moltó J; Valle M; Santos JR; Mothe B; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Barbanoj MJ; Clotet B
    Antivir Ther; 2010; 15(2):219-25. PubMed ID: 20386077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.